Vertex Pharmaceuticals Incorporated (VRTX) Vertex Announces Positive Week 36 Interim Analysis Results for Primary and All Secondary Endpoints in the RAINIER Phase 3 Trial of Povetacicept in Adults With IgA Nephropathy
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) FY 2026 Other Release